BrainsWay (NASDAQ:BWAY) PT Raised to $12.50

BrainsWay (NASDAQ:BWAY - Free Report) had its target price raised by Northland Securities from $11.00 to $12.50 in a research note released on Thursday morning, Benzinga reports. They currently have an outperform rating on the stock.

Get BrainsWay alerts:

Separately, HC Wainwright reiterated a buy rating and issued a $16.00 price target on shares of BrainsWay in a research report on Monday, September 16th.

Check Out Our Latest Report on BrainsWay

BrainsWay Stock Performance

Shares of NASDAQ:BWAY traded up $0.60 during midday trading on Thursday, reaching $9.60. 161,500 shares of the company's stock were exchanged, compared to its average volume of 95,204. The company's 50 day simple moving average is $7.80 and its two-hundred day simple moving average is $6.51. BrainsWay has a 12 month low of $3.09 and a 12 month high of $9.70. The firm has a market capitalization of $159.98 million, a PE ratio of -106.67 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. The firm had revenue of $10.01 million during the quarter, compared to analysts' expectations of $9.40 million. During the same quarter last year, the company earned ($0.05) earnings per share. On average, research analysts anticipate that BrainsWay will post 0.06 earnings per share for the current year.

Ad The Freeport Society

Elon Musk’s chilling warning for humanity

The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.

Go here to see why.

Institutional Trading of BrainsWay

Several hedge funds have recently modified their holdings of the company. Perritt Capital Management Inc bought a new stake in BrainsWay during the 2nd quarter worth approximately $121,000. Acadian Asset Management LLC increased its stake in shares of BrainsWay by 48.1% in the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company's stock valued at $1,567,000 after buying an additional 84,371 shares in the last quarter. Rhumbline Advisers increased its stake in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock valued at $110,000 after buying an additional 1,695 shares in the last quarter. Virtu Financial LLC bought a new position in shares of BrainsWay in the first quarter valued at about $60,000. Finally, Essex Investment Management Co. LLC grew its holdings in BrainsWay by 37.5% during the 1st quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company's stock worth $1,718,000 after acquiring an additional 88,593 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company's stock.

About BrainsWay

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Featured Stories

→ Gold at $2,600... But This Stock Gives You More for Under $20 (From Monument Traders Alliance) (Ad)

Should you invest $1,000 in BrainsWay right now?

Before you consider BrainsWay, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.

While BrainsWay currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report